glp-1 cardiovascular outcomes 2025 news Frontiers APhA 2025: GLP-1 Receptor Agonists
Description
Individual responses to low doses also vary widely
MA: Writing original draft, Conceptualization, Writing review & editing, Validation
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular disease shows these drugs have significant benefits in people with and without diabetes
HyQvias label expansion is based on data from the randomized, placebo-controlled ADVANCE-CIDP 1 trial and single-arm open-label extension ADVANCE-CIDP 3 trial, each of which revealed a favorable safety profile for the treatment
It's worth noting that GLP-1 receptor agonists generally have similar gastrointestinal side-effect profiles, though individual tolerance can vary between agents
Most contacts have been with Merck and Novo Nordisk
